Halozyme Therapeutics (HALO) total liabilities

Total liabilities · fiscal 2025
$2.48B

Halozyme Therapeutics (HALO) had total liabilities of $2.48B at the end of fiscal 2025 (December 31, 2025). That is 45.7% higher than the $1.70B of fiscal 2024. Figures as of 18 Nov 2026, 23:55 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$2.48B
Change on fiscal 2024
+45.7%
Highest on record
$2.48Bfiscal 2025
Lowest on record
$1.65Bfiscal 2023
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Halozyme Therapeutics total liabilities, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $2.48B in fiscal 2025 and the lowest $1.65B in fiscal 2023.

History · 4 fiscal years

Total liabilities by fiscal year

Halozyme Therapeutics total liabilities, year by year

Halozyme Therapeutics (HALO) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$2.48B 45.7% up
2024$1.70B 3.0% up
2023$1.65B 1.3% down
2022$1.67B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Halozyme Therapeutics and comparable companies
CompanyTotal liabilitiesFiscal year
Fresenius Medical Care FMS€16.72B2025
Kymera Therapeutics KYMR$163.15M2025
DaVita DVA$16.32B2025
Halozyme Therapeutics HALO$2.48B2025
Universal Health Services UHS$8.12B2025
Repligen RGEN$843.57M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on HALO

Halozyme Therapeutics, figure by figure

Halozyme Therapeutics (HALO) overview: price, valuation and scorecardAll health care companies by market value

Halozyme Therapeutics total liabilities: questions and answers

How large are Halozyme Therapeutics's total liabilities?

Halozyme Therapeutics (HALO) had total liabilities of $2.48B at the end of fiscal 2025 (December 31, 2025). That is 45.7% higher than the $1.70B of fiscal 2024.

What are the highest and lowest total liabilities figures on record for Halozyme Therapeutics?

Across the 4 fiscal years on record (2022–2025), the highest was $2.48B in fiscal 2025 and the lowest $1.65B in fiscal 2023.

How is Halozyme Therapeutics's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Halozyme Therapeutics it is on record here for 4 fiscal years, 2022 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Halozyme Therapeutics (HALO) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/HALO/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.